Pair Name	Gallic acid, Cisplatin
Disease Info	[ICD-11: 2C73]	Ovarian Cancer		Investigative
Gene Regulation	Up-regulation	Expression	CASP3	hsa836
In Vitro Model	A2780S	Ovarian endometrioid adenocarcinoma	Homo sapiens (Human)	CVCL_4863
	A2780/CP70	Ovarian endometrioid adenocarcinoma	Homo sapiens (Human)	CVCL_0135
Result	These data suggest that GA may help overcome the resistance. Hence, the cytotoxic effects of GA, especially on chemo-resistant ovarian cancer cells merit further investigation.

Pair Name	Gallic acid, Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Phosphorylation	JAK1	hsa3716
	Down-regulation	Phosphorylation	STAT3	hsa6774
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
Result	GA enhanced the anticancer effect of Pira on K562 and K562/Dox cancer cells through cellular energy status impairment, and was able to reverse drug resistance in living K562/Dox cancer cells by inhibiting the function of P‑glycoprotein.

Pair Name	Gallic acid, Cisplatin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	MCF-10A	Healthy	Homo sapiens (Human)	CVCL_0598
Result	The study showed that GA has the potential to exert the cytotoxic effects of CPT on human breast adenocarcinoma cells. Cytotoxicity of GA on cancer cells is through the induction of apoptosis and by reducing the risk of chromosomal damage. Hence, the combination of CPT and GA could represent a promising alternative therapy for breast cancer treatment with reduced doses and minimal side effects.